{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-064309","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.379688+00:00","generated_at":"2026-06-01T08:54:49.850693+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC","bullets":["Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.","Median duration of response exceeds 21 months; 95% of 12-month CR patients maintained CR for another 12 months.","Progression-free survival at 24 months was 100%; cystectomy-free survival at 24 months was 80% (100% for CR patients).","No synergistic toxicity observed; combination with pembrolizumab well tolerated.","FDA Breakthrough Therapy Designation granted in May 2023; company plans to incorporate findings into planned CORE-008 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-064309","json":"https://secwatch.observer/filing/0000950170-24-064309.json","markdown":"https://secwatch.observer/filing/0000950170-24-064309.md","text":"https://secwatch.observer/filing/0000950170-24-064309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024064309/0000950170-24-064309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024064309/ck0001991792-20240524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:54:49.850693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}